secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2026-08-11T12:07:21+00:00
Accession:  0001193125-26-343482
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo, Sentynl sign option/license deal for alvelestat in AATD-LD; up to $40M upfront, $435M milestones
--------------------------------------------------------------------------------

- Non-refundable option fee; on exercise $40M upfront/R&D, up to $435M milestones, double-digit tiered royalties on US sales.
- Sentynl gets US commercial and global manufacturing rights; Mereo keeps rest-of-world rights and leads global Phase 3.
- Alvelestat is a neutrophil elastase inhibitor; potential first oral treatment for AATD-LD affecting ~50k-80k US patients.
- Phase 3 could start early 2027; backed by positive efficacy data from two Phase 2 studies.
- Agreement dated Aug 11, 2026; parties to collaborate on manufacturing and Phase 3 design during option period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526343482/0001193125-26-343482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526343482/mreo-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer